耐药结核病化学治疗研究的过去、现状与未来

doi:10.3969/j.issn.1000-6621.2014.08.003

中国防痨杂志 ›› 2014, Vol. 36 ›› Issue (8): 634-637.doi: 10.3969/j.issn.1000-6621.2014.08.003

耐药结核病化学治疗研究的过去、现状与未来

肖和平方勇范琳刘一典

200433 同济大学附属上海市肺科医院结核病诊疗中心上海市结核病（肺）重点实验室

收稿日期:2014-07-08 出版日期:2014-08-10 发布日期:2014-09-07
通信作者: 肖和平 E-mail:xiaoheping_sars@163.com

The past, present and future of study in the chemotherapy of drug-resistant tuberculosis

XIAO He-ping, FANG Yong, FAN Lin, LIU Yi-dian

Shanghai Key Lab of Tuberculosis, Tuberculosis Center for Diagnosis and Treatment, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China

Received:2014-07-08 Online:2014-08-10 Published:2014-09-07
Contact: XIAO He-ping E-mail:xiaoheping_sars@163.com

摘要/Abstract

摘要： 耐药结核病的流行是当前结核病控制工作面临的主要挑战之一，严重威胁人们在结核病控制领域所取得的成就。抗结核药物是控制结核病的最有效武器，但面对耐多药结核病尤其是广泛耐药结核病明显力不从心，结核病有可能因此而再度成为“不治之症”。研制更有效的抗结核药物，设计具有抗耐药结核病的化学治疗方案，化解耐药结核病的治疗困境，迫在眉睫。作者通过回顾历史，着眼现在，展望未来，阐述耐药结核病化学治疗的若干问题，期待有助于读者对耐药结核病化学治疗研究有一个较为全面的认识，共同探索化学治疗控制耐药结核病流行的可行性。

关键词: 结核, 抗多种药物性/药物疗法, 临床方案, 回顾性研究

Abstract: The prevalence of drug-resistant tuberculosis (TB) is one of the main challenges on current TB control which seriously influences the achievement people had made in this field. Anti-TB drugs are the most effective weapons in controlling TB, however, they have been obviously not enough to deal with multidrug-resistant TB, especially extensively drug-resistant TB, TB is more likely to become the incurable disease again because of this reason. Therefore, it is urgent to develop more effective anti-TB drugs, design the chemotherapy regiment on drug-resistant TB and solve the difficulty in treating drug-resistant TB. The authors reviewed the history, focused on the present and looked ahead the future, elucidated several issues about treatment on drug-resistant TB and had expectation that readers would have a comprehensively understanding of chemotherapy for drug-resistant TB and make efforts altogether to explore the possibility of controlling the epidemic of drug-resistant TB by chemotherapy.

Key words: Tuberculosis, multidrug-resistant/drug therapy, Clinical protocols, Retrospective studies

肖和平，方勇，范琳，刘一典. 耐药结核病化学治疗研究的过去、现状与未来[J]. 中国防痨杂志, 2014, 36(8): 634-637. doi: 10.3969/j.issn.1000-6621.2014.08.003

XIAO He-ping, FANG Yong, FAN Lin, LIU Yi-dian. The past, present and future of study in the chemotherapy of drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2014, 36(8): 634-637. doi: 10.3969/j.issn.1000-6621.2014.08.003

参考文献

［1］Grosset J.The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.Bull Int Union Tuberc, 1978，53(1):5-12.
［2］［No authors listed］.Controlled clinieal trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet,1974, 2(7875):237-240.
［3］World Health Organization.Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva:World Health Organization,1996.
［4］World Health Organization．Global tuberculosis report 2013. Geneva：World Health Organization，2013．
［5］Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect of pyrazinamide and ofloxacin within the human macrophage.Tuber Lung Dis, 1996, 77(6):491-495.
［6］中国防痨协会. 耐多药结核病化学治疗的意见(试行). 中国防痨杂志，2003，25 (1)：4-9.
［7］中国防痨协会. 耐多药结核病化学治疗指南（2009）.中国防痨杂志，2010，32（4）：181-198.
［8］World Health Organization. Guidelines for the programmaticmanagement of drug-resistant tuberculosis. 2011 update.WHO/HTM/TB/2011.6. Geneva: World Health Organization, 2011.
［9］Sullivan EA，Kreiswirth BN，Palumbo L，et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City．Lancet，1995，345(8958)：1148-1150．
［10］肖和平.耐多药结核病化疗药物的选择与方案的制定.中华结核和呼吸杂志，2006,29(8):517-519.
［11］World Health Organization. Guidelines for the programmaticmanagement of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: World Health Organization, 2006.
［12］吴惠忠，尹建军，钟耐容，等. 广东省全球基金耐多药结核病项目阶段性实施情况分析.中国防痨杂志, 2013,35(10): 799-802.
［13］唐神结，肖和平. 利奈唑胺抗结核作用的研究及其最新进展. 中华临床医师杂志(电子版)，2010，4（1）：63-66．
［14］中国防痨协会结核病临床专业委员会.结核病临床诊治进展年度报告（2012年）（第二部分结核病临床治疗）.中国防痨杂志,2013,35(7):488-510.
［15］Nuermberger EL，Spigelman MK，Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology,2010,15(5)：764-778.
［16］Ma Z，Lienhardt C，McIlleron H，et al．Global tuberculosis drug development pipeline: the need and the reality.Lancet，2010，375（9731）：2100-2009.
［17］Diacon AH，Donald PR，Pym A，et al．Randomized pilot trial of eight weeks of bedaquiline（TMC207） treatment for multidrug-resistant tuberculosis：long-term outcome，tolerability，and effect on emergence of drug resistance. Antimicrob Agents Chemother,2012,56(6):3271-3276.
［18］Gler MT，Skripconoka V，Sanchez-Garavito E，et al．Delamanid for multidrug-resistant pulmonary tuberculosis．N Engl J Med, 2012, 366(23):2151-2160．
［19］Skripconoka V，Danilovits M，Pehme L，et al．Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J,2013，41(6)：1393-1400．
［20］World Health Organization.Joint meeting of the global GLC Committee and the MDR-TB Core Group.Geneva: World Health Organization, 2013.
［21］Cox H，Ford N．Linezolid for the treatment of complicated drug-resistant tuberculosis：a systematic review and meta ana-lysis．Int J Tuberc Lung Dis，2012，16（4）:447-454．
［22］Rosenthal IM,Zhang M，Williams KN，et al．Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med, 2007,4(12):e344．

[1]	许岩, 路希维, 蔡春葵, 孙诗学, 顾晓峰, 于洋, 李刚, 王颖. 治疗失败耐多药肺结核患者CT征象演变的回顾性分析[J]. 中国防痨杂志, 2020, 42(6): 549-557.
[2]	张培泽, 付亮, 谭洁, 王玉香, 陈涛, 邓国防. 耐多药肺结核临床治愈患者CT随访转归征象的研究[J]. 中国防痨杂志, 2020, 42(6): 558-562.
[3]	何敏, 蒲育, 蔡玉郭, 李邦银, 何磊, 环明苍. 23例脊柱结核并发艾滋病患者的手术疗效观察[J]. 中国防痨杂志, 2020, 42(5): 454-458.
[4]	赵本南, 刘大凤, 刘亚玲, 杨铭, 兰丽娟, 杜清. 含丙硫异烟胺和对氨基水杨酸方案治疗耐多药结核病患者致甲状腺功能减退症的临床分析[J]. 中国防痨杂志, 2020, 42(5): 465-471.
[5]	《耐药脊柱结核临床诊疗专家共识》编写组. 耐药脊柱结核临床诊疗专家共识[J]. 中国防痨杂志, 2019, 41(4): 377-382.
[6]	冯军鹏,李义帅,秦学博,李建行,李玉琢,魏兰. 胸腔冲洗在结核性支气管胸膜瘘术前治疗中的价值(附68例报告)[J]. 中国防痨杂志, 2019, 41(4): 466-468.
[7]	范琳,熊坤龙,肖和平. 建国70年来结核病化学治疗的历史进程要览[J]. 中国防痨杂志, 2019, 41(11): 1145-1148.
[8]	孙雯雯,楼海,孙勤. 含利福布汀方案治疗缓慢生长型非结核分枝杆菌肺病的短期疗效分析[J]. 中国防痨杂志, 2018, 40(9): 948-953.
[9]	金龙,胡卫华,卢水华. 糖尿病对耐多药肺结核的影响与对策[J]. 中国防痨杂志, 2018, 40(9): 999-1002.
[10]	徐彩红,张慧,阮云洲,高雨龙,张修磊,侯双翼,彭颖,李建伟,胡慧懿,李仁忠. 我国六省(自治区)全球基金项目地区耐多药肺结核诊疗效果的回顾性分析[J]. 中国防痨杂志, 2018, 40(6): 559-563.
[11]	王茂军,马丙乾,郝俊玲,付志华,董淑敏,曹艳竹. 不同方案治疗单耐异烟肼或利福平肺结核患者的预后分析[J]. 中国防痨杂志, 2018, 40(3): 286-291.
[12]	何贵清,孙峰,苏菲菲,施伎蝉,朱海燕,戴建义,杨守峰,宁洪叶,崔小亚,李君桦,蒋贤高,张文宏. 2013—2015年温州市耐多药肺结核患者队列标准化疗方案的治疗转归[J]. 中国防痨杂志, 2018, 40(2): 161-167.
[13]	方勇，肖和平. 潜伏性结核感染的诊治进展[J]. 中国防痨杂志, 2016, 38(2): 144-147.
[14]	杜鹃，田丹，陈国玺，姚芳，陈俊，兰星，袁保东. 初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J]. 中国防痨杂志, 2016, 38(11): 968-972.
[15]	杜建，钟球，傅衍勇，等. 复治肺结核患者处治时使用利福类药物剂量的调查[J]. 中国防痨杂志, 2016, 38(1): 42-46.

耐药结核病化学治疗研究的过去、现状与未来

The past, present and future of study in the chemotherapy of drug-resistant tuberculosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

友情链接